W. Edwin Fann: A History of the Tennessee Neuropsychiatric Institute


Thomas A. Ban’s reply to Barry Blackwell’s comment


         Thank you very much, Barry, for your stimulating comment (Blackwell 2020).  You are on target: the central theme of our research was the development of a clinical methodology that would identify psychiatric populations which are pharmacologically homogenous in terms of responsiveness to psychotropic drugs. My interest in this theme has continued after the TNI years and, in 2006, I was invited to the annual meeting of the Hungarian Association  of Psychopharmacology to review our findings in this area  of research in a historical perspective titled “Towards a Clinical Methodology for Neuropsychopharmacological Research.” Subsequently, the full text of this presentation was published in Neuropsychopharmacologia Hungarica, the journal of the Society.

         In the following the same text is presented with the permission of Gabor Faludi, the editor in chief of the journal.



         Neuropsychopharmacology is dedicated to the study of the pathophysiology and treatment of mental pathology with the employment of centrally acting drugs.   In neuropsychopharmacological research the clinical effects of a psychotropic drug are linked to the effects of the substance on brain structures involved in its mode of action. It is assumed, that knowledge about the mode of action of a selectively effective psychotropic drug will provide clues about the pathophysiology of the illness, and conversely, that knowledge about the pathophysiology of an illness, will provide clues for developing clinically more effective psychotropic drugs. Since the currently employed clinical methodology for the demonstration of therapeutic efficacy links the mode of action of psychotropic drugs to pharmacologically heterogeneous populations, neuropsychopharmacological research does not provide the necessary feedback for developing more effective drugs. To resolve the pharmacological heterogeneity within currently used diagnoses, attempts were made to split syndrome-based psychiatric diagnoses into discrete neurobiological deficits, and to. replace traditional psychiatric nosology by a genetic psychiatric nosology. Yet, to date, there is no alternative methodology to psychopathology-based psychiatric nosology for classifying mental pathology in a clinically relevant manner. As we are moving from the “neurotransmitter era” to a “genetic era” in neuropsychopharmacology, the need for identifying pharmacologically homogenous populations is becoming imminent. All primary targets of psychotropic drugs in the brain are encoded by genes which are identified, and any nosologic entity or psychiatric syndrome that corresponds with a treatment responsive population is a candidate for the generation of genetic hypotheses relevant to mental illness. Recognition that progress in neuropsychopharmacology, and molecular genetic research, depends on the speed clinical research can resolve the pharmacological heterogeneity within currently used diagnoses, led to the development of methodologies for the identification of treatment responsive form(s) of illness, such as the Composite Diagnostic Evaluation (CODE) System, and nosologic homotyping. The CODE System is a methodology for the identification of treatment responsive forms of illness if covered up by consensus-based diagnoses; it consists of a set of diagnostic algorithms that can assign simultaneously a diagnosis from several classifications to a patient  Nosologic homotypes are identical in elementary units of mental illness and are assigned the same position in the nosologic matrix, based on three nosologic organizing principles. The empirically derived diagnostic categories are suitable for testing hypotheses relevant to the relationship between the “processing of mental events” and “signal transduction” in the central nervous system. 

Keywords: alternative phenotypes, genetic classification, CODE System, CODE-DD, neuropsychopharmacological research; nosologic homotyping, nosologic matrix; polarity, psychopathologic symptoms, temporal organization, totality



         The therapeutic and commercial success of chlorpromazine in the mid-1950s generated interest to develop drugs for psychiatric indications (Caldwell 1970). By the end of the 1950s there were at least 22 new drugs for the treatment of different psychiatric disorders (Ban 200a; Ban and Ucha Udabe 2006). With the introduction of drugs with demonstrable therapeutic efficacy pharmacotherapy was receiving a steadily increasing share in the treatment of mental illness, and psychopharmacology became part of the teaching curriculum in psychiatry.

         The term, psychopharmacology, was introduced in 1920 by David Macht, an American pharmacologist, to describe the effects of drugs on psychometric performance tests (Macht 1920). In the 1940s, with the availability of the psychotomimetic, lysergic acid diethylamide (Hofmann 1970), research in psychopharmacology was extended to the study of model psychoses; and in the 1950s, with the rapidly growing number of psychotherapeutic drugs, it also embraced efficacy studies for the demonstration of the effectiveness of new treatments (Ban, 1996, 2004).

         Simultaneously with the introduction of psychotropic drugs, there was a shift in the understanding of signal transduction in the brain from a purely electrical to a chemically mediated event; and by the end of the 1950s there were six chemical neurotransmitters identified in the central nervous system (CNS) (Ban 2001a). Recognition of chemical mediation at the site of the synapse, coupled with the introduction of the spectrophotofluorometer  (Bowman, Caulfield and Udenfriend 1955) -- an instrument with a resolution power to measure the concentration of cerebral monoamines, such as norepinephrine and serotonin, involved in neuronal transmission at the synapse-- led to the development of neuropharmacology, the discipline dedicated to the study of the mode of action of psychotropic drugs (Ban 1996). Previously, research dealing with centrally acting drugs, was restricted to behavioral pharmacology, and neurophysiological measures (Simon 1998). Spectrophotofluorometry provided direct access to the detection of the biochemical changes responsible for the clinical effects (Ban 1999). 

         Developments in pharmacotherapy, psychopharmacology and neuropharmacology triggered the development of neuropsychopharmacology, a composite discipline, dedicated to the study of the pathophysiology and treatment of mental pathology with the employment of centrally acting drugs (Ban 2004). The new discipline has grown on the premise that research on the mode of action of psychotropic drugs with well-defined, selective therapeutic indications will generate the necessary knowledge about the pathophysiology of psychiatric disorders to guide the development of more effective pharmacological treatments.  

         By the late 1950s, the neurotransmitter era, the first epoch in the history of neuropsychopharmacology, was in progress (Ban and Ucha Udabe 2006).


The Neurotransmitter Era 

         In the neurotransmitter era neuropsychopharmacological research in the pathophysiology and treatment of mental illness was guided by knowledge derived from the effects of psychotropic drugs on neurotransmitter dynamics and metabolism (Pletscher 2006);  psychotropic drug development was driven by a rapidly developing technology that provided neuropharmacology with a capability to determine the regional distribution of neurotransmitters (Kety and Elkes 1961), the effect of drugs on the release and uptake of neurotransmitters (Axelrod, Whitby and Hertting 1961), and the affinity of drugs to neurotransmitter receptors (Snyder, Creese and Burt 1975).

         The variations in therapeutic responsiveness to the same drug in a diagnostic category focused attention on the pharmacological heterogeneity within the diagnostic groups (Ban 1969). Yet, no attempt was made to resolve the heterogeneity by the identification of pharmacologically homogenous populations that respond selectively to one or another psychotropic drug (Ban 1999).  The difficulties, created by the pharmacological heterogeneity within the diagnostic groups for the demonstration of therapeutic efficacy, were overcome by the adoption of a statistical methodology, the randomized clinical trial (RCT).

         RCTs made it possible to detect the therapeutic effects of psychotropic drugs in pharmacologically heterogeneous diagnostic populations. By providing a means for the demonstration of statistically significant superior efficacy of a psychotropic drug to an inactive placebo in a diagnostic group without the identification of the characteristics of the treatment responsive subpopulation within the diagnostic group (Ban 2006), RCTs led to semi-finished products in the treatment of mental illness. They also deprived neuropsychopharmacological research from the necessary feedback to develop clinically more selective and thereby more effective psychotropic drugs.

         RCTs had a major impact on drug regulation and on the clinical use of psychotropic drugs. By accepting that a drug is effective in a particular population if statistically significantly superior to an inactive placebo with a 0.05 or greater level of probability in two pivotal studies, authorities, in the US, Canada, and some other countries, approve the use of a psychotropic drug in a diagnostic group in which only 2 of 8 patients show a favorable response to its pharmacological effects.   Such a narrow difference between the active drug and placebo marginalizes the importance of pharmacological treatment and blurs the difference between pharmacological and other treatments. In the absence of the identification of the treatment responsive form of illness, the potential benefits of drugs may be compromised by their indiscriminate use (Ban 2006; Ban and Ucha Udabe 2006).

         In neuropsychopharmacological research the effect of a psychotropic drug on mental illness is linked with the effect of the substance on brain structures involved in its mode of action (Ban 2002). By linking the mode of action of a drug with a pharmacologically heterogeneous diagnostic population, psychopharmacologic research does not provide the necessary feedback for progress in treatment.

         As we are moving forward from the neurotransmitter era to a genetic era in neuropsychopharmacology, the gap between a neuropharmacology, with the capability to tailor drugs to receptor affinities by the employment of a rapidly growing genetic technology, and a psychopharmacology, with a methodology that is capable only to demonstrate therapeutic efficacy, has become so wide that it interferes with progress in the pharmacotherapy of mental illness. 

         The inconsistent and conflicting findings in molecular genetic research led to a steadily growing dissatisfaction (Hyman 1999) with consensus-based diagnoses and classifications, such as the DSM-IVTM of the American Psychiatric Association (1994), and the ICD-10 of the World Health Organization (1992).  Since all the primary targets of psychotropic drugs in the brain, e.g., G-protein coupled receptors, nuclear hormonal receptors, ion channels, enzymes, etc., are encoded by genes that have been identified, any nosologic entity that corresponds with a treatment responsive population is suitable for the generation of genetic hypotheses relevant to mental illness (Ban 2002).


Towards a Genetic Era            

         By the late 20th century the dissatisfaction with the clinical end points given in consensus-based classifications was so severe that it was proposed to re-conceptualize mental illness in terms of genetically meaningful “discrete neurobiological deficits,” also referred to as “alternative phenotypes,” such as the “abnormality of smooth pursuit eye movement” (Holzman, Kringlen, Mathysse et al. 1988) linked to a locus on the short arm of chromosome 6 (Arolt, Lencer, Nolte et al. 1996), and the “P-50 evoked response deficit” (Freedman, Adler and Leonard 1999) linked to the α1-nicotinic acid receptor on the long arm of chromosome 15 (Freedman, Coon, Myles-Worsley et al. 1997). Nevertheless, the usefulness of these “alternative phenotypes” in biological research in schizophrenia is questionable because both “phenotypes” are encountered several times more frequently in the general population than schizophrenic disorders (Faraone, Tsuang and Tsuang 1999).

         It has also been suggested to replace traditional psychiatric nosology by a  “genetic psychiatric nosology” which would classify patients into categories that “correspond with the genes.” While such a nosology could focus attention on overlaps between certain traits, e.g., depression and anxiety, it would group together individuals who fully qualify for a particular disease and individuals who, despite carrying the genes for the disease, are symptom free (Faraone, Tsuang and Tsuang 1999).

         Recognition that to-date there is no alternative methodology to psychopathology-based psychiatric nosology for classifying mental pathology in a clinically relevant manner (Ban 2002), stimulated interest in linear regression equations for the identification of the treatment responsive form(s) of illness within the currently used diagnoses. However, findings with linear regression analyses of rating scale scores -- generated in clinical drug trials designed for the demonstration of therapeutic efficacy -- were inconsistent (Ban 1987; Roth and Barnes 1981). Rating scales constructed for the assessment of change in the severity of psychopathology, are sensitized by the omission of psychopathological symptoms that are not influenced by treatment, or by the retention of only those symptoms that show the largest changes (Ban 1999). While sensitized scales are eminently suited for the demonstration of the efficacy of a drug in the shortest possible time in the smallest number of patients, they preclude the possibility of findings any relevant information for the identification of treatment-responsive forms of illness by metanalyses in the data of RCTs with psychotropic drugs (Ban 2006).


The CODE System 

         There are two diagnostic instruments in development to provide pharmacologically more homogenous populations for research than the diagnostic categories of consensus-based classifications: the Composite Diagnostic Evaluation (CODE) System, and Nosologic Homotyping. The CODE System is a methodology for the identification of the treatment responsive form of illness if covered up by consensus-based, or other broadly defined diagnoses. An important impetus for the development of the CODE-System was the finding of Frank Fish that the traditional diagnostic concept of schizophrenia covered up the powerful effectiveness of phenothiazine neuroleptics in a subpopulation of schizophrenia (Fish 1964). With the employment of Karl Leonhard’s classification of “endogenous psychoses,” he revealed that 3 of 4 patients with unsystematic schizophrenia, one of the two classes of disease subsumed under the diagnosis of schizophrenia, responded favorably to neuroleptic phenothiazines, whereas only about 1 of 4 patients with systematic schizophrenia  showed a similar favorable response. Response rate in affect-laden paraphrenia, one of the three forms of unsystematic schizophrenia was about 85%, whereas in the different forms of systematic schizophrenia, response rates were below 25% (Fish 1964; Leonhard 1957)

         The CODE System consists of a set of diagnostic instruments (“CODES”) that can provide for polydiagnostic evaluation in distinct categories of mental illness by the employment of an integrated criteria list and standardized data collection. Each CODE consists of a vocabulary, or set of variables (“codes”), that includes all the elementary units (variables) of the diagnoses in the component classifications; a structured interview, that provides algorithms for the determination of the presence or absence of each variable; and diagnostic decision trees that provide diagnoses in all the component diagnostic systems (Ban 1991). In addition, each CODE includes a rating scale, based on a subset of variables from the vocabulary, for the determination of the severity of the clinical state across diagnoses. A unique characteristic of the CODE System is that it provides readily accessible information relevant to the diagnostic process from the lowest to the highest level of decision-making. The first set of provisional CODEs included polydiagnostic algorithms for anxiety disorders (CODE-AD), depressive disorders (CODE-DD), hyperthymic disorders (CODE-HD) and schizophrenic disorders (CODE-SD) (Ban 2001b; Gaszner and Ban 1998).



         The prototype of the CODE System is CODE-DD, the CODE for unipolar depressive disorders (Ban 1989).  One of the contributing factors to its development was the recognition that the diagnosis of “vital depression” was covered up in consensus-based classifications, such as the DSM-III (American Psychiatric Association 1980). Vital depression, characterized by “corporization,” “disturbance of vital balance” and the “feeling of loss of vitality” (Schneider 1920, 1950, 1959), is the form of depression that provided Roland Kuhn, the necessary diagnostic end-point to recognize the antidepressant effect of imipramine (Kuhn 1957). In currently used consensus-based classifications, the diagnosis of “vital depression” is covered up to the extent that even in a severely ill patient who displays all the possible symptoms and signs considered for the DSM-III, DSM-III-R and DSM-IV (American Psychiatric Association 1980, 1987, 1994) diagnoses of “major depression,” and the ICD-10 (World Psychiatric Association 1992) diagnosis of “depressive episode,” one still would not know whether the patient qualifies for vital depression..

         CODE-DD consists of a 90-items vocabulary, a structured interview, a 40-items severity subscale, and 25 diagnostic decision trees. Of the diagnostic systems included in CODE-DD, three are based on the conceptual development of the classifications of depressive disorders in Europe (Kraepelin 1896, 1921; Leonhard 1957; Schneider 1959); and three on the conceptual development of classifications in North America (Feighner, Robins, Guze et al. 1972; Robins and Guze 1972; Spitzer, Endicott and Robins 1978); two are consensus-based classification, one based primarily on the consensus of experts in the USA (American Psychiatric Association, 1987) and one on the consensus of experts in Europe (World Health Organization 1988); 10 are empirically derived  classifications, the result of factor or  cluster analyses of psychiatric rating scales (Foulds  1973, 1976; Hamilton and White 1959; Lewis 1934; Kiloh and Garside 1963; Mendels and Cochrane 1968; Overall, Hollister, Johnson et al. 1966; Paykel 1971; Pilowsky, Levine and Boulton 1969; Raskin and Crook 1976; Wing, Cooper and Sartorius 1974); six are miscellaneous classifications (Berner, Gabriel, Katschnig et al. 1983; Kielholz 1972; , Klein 1973, 1974; Pollitt 1965; Taylor 1986; Winokur 1974, 1979); and one is a composite diagnostic classification, based on the different classifications included in CODE-DD.

         One would expect low inter-rater agreement in such a complex system like CODE-DD. However, in the first reliability study that included 239 patients there was an 87.8% inter-rater agreement on the presence or absence of the 90-items of the vocabulary (Morey 1991). In the second, inter-rater agreement increased to 100% (Ban, Fjetland, Kutscher et al. 1993). In a validation study that included 230 of patients with a clinical diagnosis of major depression, there was a 99.6% correspondence between the clinical DSM-III-R and CODE-DD diagnosis of major depression. In another validation study, which included 322 patients, the correspondence was 97.2% (Ban, Fjetland, Kutscher et al. 1993). CODE-DD was translated and adopted from the English original (Ban 1987) into Estonian (Mehilane 1992), French (Ferrero, Crocq and Dreyfus 1992), Italian (Aguglia and Forti 1989), Polish (Puzynski, Jarema and Wdowiak 1989), and Portuguese  (Nardi and Versiani 1990). It was used in a series of clinical studies in the early development of reboxetine, a selective NE re-uptake blocker  (Ban, Gaszner, Aguglia et al. 1998).

         Findings with CODE-DD correspond with the commonly held view that the DSM-III-R diagnosis of major depression is a broad diagnostic category. If depressive illness were characterized by unmotivated depressed mood, depressive evaluations, and lack of reactive mood changes, from the 322 patients with the clinical diagnosis of major depression --included in the second validation study-- only 119 patients, i.e., 37% would have qualified for depression.  Findings with CODE-DD are also in keeping with the notion that depression consists of more than one form of illness. From the 322 patients only 95 patents, i.e., 29.5%, fulfilled definite criteria of Kraepelin’s depressive states, characterized by motor retardation, retardation of thought and difficulties of concentration (Kraepelin 1896), and even less, 45 patients, i.e., 14%, fulfilled criteria of Schneider’s vital depression (Schneider 1920). The overlap between the two forms of depressive illness was negligible (Ban 2001b)



         To extend the scope of CODE-DD for uncovering depressive diagnoses, the instrument was revised. In the revised instrument (CODE-DD-R), also referred to as CODE-UD, the vocabulary was increased from 90 to 220 variables, and the number of diagnostic algorithms from 25 to 84. CODE-UD includes all major diagnostic concepts and classifications of melancholia/depression from Hippocrates (460-377 BC) to the DSM-IV(American Psychiatric Association 1994).

         The term “melancholia” was first used in the 5th century BC, in reference to all chronic mental syndromes that did not qualify for epilepsy, hysteria, or Scythian disease (transvestism), in the Works of Hippocrates  (Adams 1929). Until the late 18th century the concept of melancholia had virtually no relationship with our current concept of depression; Boissier de Sauvages classified the melancholias as disorders of intellect  (Sauvages de la Croix 1769) and Willam Cullen as disorders of judgment  (Cullen 1772).

         Development of our current conceptual framework relevant to depressive illness began in the early 19th century by Johann Christian Heinroth’s recognition that melancholia is a disorder of affect. Heinroth (1818) perceived insanity as exaltation or depression of one of three faculties (emotion, intellect, volition) of the mind, and classified melancholia as partial insanity that is characterized by depression of emotions. (Heinroth 1818). Twenty years later, by separating lypemania (lupos=sadness), or melancholy of the ancient (Healy 1997) from the monomanias (intellectual, affective and instinctive), Jean-Etienne Dominique Esquirol set the stage for a development that led to our current diagnostic concepts and classifications of depression (and also of other mental disorders) (Esquirol 1838).      


Nosologic  Homotyping 

         The need for a pharmacologically valid, empirically derived nosology was first expressed in the late 1950s by Fritz Freyhan, a German born American psychiatrist. He recognized the differential responsiveness to the same psychotropic drug in the same (Kraepelinian) diagnostic category and suggested a pharmacological re-evaluation of psychiatric nosology with the employment of target symptoms and diagnoses (Freyhan 1959; Shorter 2005).

         Nosologic homotyping is a methodology for the development of an empirically derived, pharmacologically valid, classification of mental disorders. Nosologic homotypes are identical in “elementary units” of mental illness and are assigned the same position in the “nosologic matrix” constructed with the employment of nosologic organizing principles (Ban 2002)

         The elementary units of mental illness are psychopathologic symptoms; each psychopathologic symptom has a content derived from past experience, and a form, characteristic of the illness (Jaspers 1910, 1913). Each psychopathologic symptom represents a distinct pathology in the processing of mental events, and each psychopathological symptom profile, is a “phenotype” of a mental disorder. The temporal organization of the psychopathologic symptoms reflects the pathological process in its ”dynamic totality,” and the “dynamic totality” of the pathological process, together with the “totality” and “polarity” of the clinical picture, provides a “structure” that is determined by the illness (Ban 1987). It is in terms of this “determining structure,” that each mental illness is defined and assigned a place in the “nosologic matrix” based on three nosologic organizing principles (Ban 2002).

         The first organizing principle of psychiatric nosology is ”totality,” i.e., the  inclusiveness of the psychopathologic process (Ban 1970). It was the organizing principle in the classification of Cullen (1772), Esquirol (1838), Kahlbaum (1863), and many others. On the basis of “totality,” insanity is divided into “universal“ (“total”) and “partial”; in “partial insanity,” in contrast to “universal insanity,” personality remains preserved. The concept of  “partial insanity” was extended to include  “abortive” (distinct from “true”), “selective” (distinct from “universal”) and “incomplete” (distinct from “complete”) mental illness (Ban 2000).   In “abortive” mental illness patients are aware (have insight) that their thinking and/or feelings and/or actions are pathological (Westphal 1878); in “selective” mental illness, the pathology of mental integration is restricted to one (or two) of the three field(s) of consciousness, i.e., the external world (“allopsychic”), the self (“autopsychic”), and the body (“somatopsychic”) (Wernicke 1899); and in “incomplete“ mental illness the pathology is restricted to one or two of the three components of the “psychic reflex,” i.e., afferent (“perceptual-cognitive”), central (“relational-affective”) and efferent (“motor-adaptive”) (Leonhard 1957).

         The second organizing principle of psychiatric nosology is the temporal organization of the psychopathologic process, i.e., the “onset” (“sudden” vs “insidious”), “course” (“episodic” vs. “continuous”) and “outcome” (“recovery” vs “defect”).  It was the organizing principle of mental illness in the sixth edition of Kraepelin’s textbook (Kraepelin 1899), and has remained the organizing principle in the classifications of mental illness to-date. On the basis of the temporal organization of psychopathologic symptoms “attacks,” i.e., episodes that last from minutes to hours, are distinguished from “phases,” i.e., episodes that last from days to years, and from “periods,” i.e., “phases” that recur with regularity; and “thrusts,” i.e., acute events that yield lasting changes, are distinguished from “ continuous process,” i.e., chronic events that yield highly differentiated irreversible “end-states,” and from “progressive deterioration,” i.e., chronic events that yield severe dedifferentiation terminating in irreversible dementia  (Jaspers 1913).

         The third organizing principle of psychiatric nosology is the spatial organization of the psychopathologic process, i.e., “polarity” of the psychopathological process. The origin of the concept of “polarity,” is in Edda Neele’s evaluation of phasic sicknesses diagnosed between 1938 and 1942 in Karl Kleist’s “clinic” in Frankfurt (Neele 1949; Teichmann 1990). Polarity was to become the dominant organizing principle in Karl Leonhard’s classification of endogenous psychoses in which “monopolar” (“simple”) psychoses, such as the phasic psychoses and systematic schizophrenias, were separated from the “bipolar” (“multiform”) psychoses, such as manic-depressive disease, the cycloid psychoses and the unsystematic schizophrenias (Leonhard 1957). Within Leonhard’s frame of reference, bipolar illness swings between two poles of mood and/or emotions and/or motility, and displays a continuously changing, variable clinical picture, whereas “unipolar” illness is restricted to one pole of mood and/or of emotions and/or of motility, and displays the same symptomatology within and across episodes. Each form of “unipolar” illness is distinct and characterized by a syndrome associated with no other forms and not even transitionally related to any other form.

         Nosologic homotypes are more homogenous populations in terms of psychopathology than populations identified by any of the available diagnostic instruments. If nosologic homotyping would identify pharmacologically or genetically homogenous populations it would indicate that phenomenological psychopathology and psychiatric nosology could provide the key for the delineation of biologically meaningful disease categories in psychiatry. By linking the mode of action of psychotropic drugs to pharmacologically homogeneous populations, nosologic homotyping could break the impasse in progress of neuropsychopharmacological research, pharmacotherapy and molecular genetic research in mental illness (Ban 2002).

         Furthermore, considering that “nosological homotypes” are defined in terms of their effect on processing of mental events and psychotropic drugs are defined in terms of their effects on “signal transduction” in the brain, the empirically derived diagnostic categories could provide clinical entities which are suitable for testing hypotheses relevant to the relationship between processing of mental events and “signal transduction” in the central nervous system. Thus, “nosologic homotyping” could open the path for the development of a psychiatry in which mental pathology is perceived in terms of pathology in “signal transduction” in the brain and for a rational pharmacotherapy of mental illness.  


Concluding Remarks   

         Recognition of a possible relationship between drug-induced changes in psychopathology and in the concentration of monoamine neurotransmitters and their metabolites in the brain led to the formulation of the hypothesis that the psychotropic effects of drugs are related to their action on the transmission (processing) of impulses at the synaptic cleft (Ban 2000, 2002, 2006; Brodie, Shore and Pletscher 1956a,b; Pletscher, Shore and Brodie 1955, 1956; Shore, Silver and Brodie 1955a,b). The notion that drugs exert their psychotropic effects through the modification of transmission of impulses from one neuron to another has far reaching heuristic implications for psychiatry. The cerebral cortex of the human brain contains about 10 billion neurons, with about one million billion connections, of which the majority communicates only with each other (Edelman 1992). The lack of consistent biological manifestations in mental illness has raised the possibility that the site of mental pathology is the major compartment of the cerebral cortex that has no direct contact with either sensory input or behavioral output (Ban 2004). If this is the case, the primary manifestations of the psychiatric disease process are psychopathological symptoms and nosologic entities, i.e., patterns of psychopathologic symptoms (Ban 1987), and nosologic homotyping is a suitable methodology for rendering the morphologic substrate of mental pathology accessible to scientific scrutiny.



Adams F. Genuine Works of Hippocrates. Translated from the Greek. New York,        William Wood & Co. 1929.

American Psychiatric Association. DSM-III. Diagnostic and Statistical Manual of Mental Disorders. Third Edition. Washington, American Psychiatric Association. 1980.

American Psychiatric Association. DSM-III-R Diagnostic and Statistical Manual of Mental Disorders. Third edition. Revised. Washington, American Psychiatric Association. 1987.

American Psychiatric Association. DSM-IVTM Diagnostic and Statistical Manual of Mental Disorders. Fourth edition. Washington, American Psychiatric Association. 1994.

Arolt V, Lencer R, Nolte A, Müller-Myhsok B, Purmann S, Schürmann M, Leutelt J, Pinnow M, Schwinger E. Eye tracking dysfunctions a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am. J. Med. Genet. 1996; 67:564-79.

Axelrod J, Whitby LG, Hrtting G. Effect of psychotropic drugs on the uptake of 3H-norepinephrine by tissues. Science 1961; 133:383-4. 

Ban TA. Psychopharmacology. Baltimore, Williams & Wilkins, 1969, p. 431.  

Ban TA. Prolegomenon to the clinical prerequisite: Psychopharmacology and the classification of mental disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1987: 11:527-80. 

Ban TA, CODE-DD Composite Diagnostic Evaluation of Depressive Disorders.  Nashville, JM Productions. 1989. 

Ban TA. CODE System: theory and practice. In: Aguglia E, Ban TA, editors. Functional Psychoses Today. Rome, John Libbey. 1991.

Ban TA. They used to call it psychiatry. In: Healy D, editor. The Psychopharmacologists. London/Weinham/New York/Tokyo/Melboune/Madras, Altma, An Imprint of  Chapman and Hall, 1996, pp. 587-620.

Ban TA. Selective drugs versus heterogenous diagnoses towards a new methodology in neuropsychopharmacological research. Psiqiatria Biologica, 1999; 7:177-89. 

Ban TA. Nosology in the teaching of psychiatry. J. bras.psiquiatr. 2000; 49:39-49. 

Ban TA. Pharmacotherapy of mental illness. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 2001a; 25:709-27. 

Ban TA. The CODE System in psychiatry. Neuropsychopharmacol. Hung. 2001b; 3:6-10.  

Ban TA. Neuropsychopharmacology: the interface between genes and psychiatric nosology. In: Lader, B. (ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge, Cambridge University Press, 2002, pp. 36-56. 

Ban TA. Neuropsychopharmacology and the history pf pharmacotherapy in psychiatry. A review of developments in the 20th century. In: Ban TA, Healy D, Shorter E, editors. Reflections on Twentieth-Century Psychopharmacology. Budapest, Animula, 2004, pp. 697-720. 

Ban TA. Academic psychiatry and the pharmaceutical industry. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2006; 30:429-41. 

Ban TA, Ucha Udabe R. The neurotransmitter era in neuropsychopharmacology. In: Ban TA, Ucha Udabe R, editors. The Neurotransmitter Era in Neuropsychopharmacology. Buenos Aires, Polemos, 2006, pp. 265-74. 

Ban TA, Gaszner P, Aguglia E, Batista R, Castillo A, Lipcsey A, Macher J-P, Torres-Ruis A, Vergara L. Clinical efficacy of reboxetine: a comparative studywith desipramine with methodological considerations. Human Psychopharmacology, 1998; 13 (suppl. 1):29-39. 

Ban TA, Fjetland OK, Kutscher M, Morey LC. CODE-DD development of a diagnostic scale for depressive disorders. In: Hindmarch IM, Stonier PD, editors. Human Psychopharmacology. Measures and Methods. Vol. 4. Chichester, John Wiley& Sons, 1993, pp. 73-85.

Ban TA. Towards a Clinical Methodology for Neuropsychopharmacological Research. Neuropsychopharmacologia Hingarica, 2007; 9:81-90.

Berner P, Gabriel E, Katschnig H, Kieffer W, Koehler K, Lenz G, Simhandl, C. Diagnostic Criteria  for Schizophrenia and Affective Psychoses. Washington, World Psychiatric Association and American Psychiatric Association. 1983. 

Blackwell B. Comment on Thomas A. Ban’s comment titled “Central theme of clinical research  at the TNI from  the mid-1970s to the 1980s” (W. Edwin Fann: A History of the Tennessee Neuropsychiatric Institute). inhn.org.perspective. February 13, 2020. 

Bowman RL, Caulfield PA, Udenfriend S. Spectrophotofluorometry in the visible and the ultraviolet. Science, 1955; 122:32-3. 

Brodie BB, Shore PA, Pletscher A. Limitation of serotonin-releasing activity to those alkaloids possessing tranquilizing action. Science, 1956a; 123:992-3. 

Brodie BB, Pletscher A, Shore PA. Serotonin as a mediator of reserpine action in brain.  J. Pharmacol. Exp. Therap. 1956b; 116(1):84-9.  

Caldwell AE. Origins of Psychopharmacology. From CPZ to LSD. Springfield, Charles C. Thomas, 1970, pp. 43-6. 

Cullen W. Synopsis Nosologiae Methodicae. Edinburgh, A. Kincaid & Creech. 1772. 

Esquirol JED. Des maladies mentales. vol.2.  Paris, Bailliere. 1838.                                       

Edelman GM. Bright Air, Brilliant Fire. On the Matter of the Mind. New York, Basic Books. 1992. 

Faraone SV, Tsuang MT, Tsuang DW. Genetics of Mental Disorders. New York, Guilford Press. 1999. 

Feighner JP, Robins E, Guze SB, Woodruff JP, Winokur G, Munoz R.  Diagnostic criteria for use in psychiatric research. Arch Gen. Psychiatry, 1972; 26:57-63.

Ferrero F, Crocq M-A, Dreyfus F. Thomas A. Ban CODE-DD Evaluation diagnostique composite des troubles depressifs. Geneve, Editions Medicine  et Hygiene, 1992, pp. 1-247.

Fish F. The influence of the tranquilizer on the Leonhard schizophrenic syndromes. Encephale 1964; 53:245-9.

Foulds G. The relationship between te depressive illnesses. Br. J. Psychiatry, 1973; 122:531-3.

Foulds G. The Hierarchical Nature of Personal Illness. Orlando, Academic Press. 1976.

Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. Linkage of neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA, 1997; 94:587-92.

Freedman R, Adler LE, Leonard S. Alternative phenotypes for the complex genetics of schizophrenia. Biol. Psychiatry, 1999; 45:551-8. 

Freyhan F. Selection of patients from the clinical point of view. In: Cole JO, Gerard RW, editors. Evaluation of Pharmacotherapy in Mental Illness. Washington, National Academy of Sciences, 1959, pp. 372-89.

Gaszner P, Ban TA. CODE-HD Composite Diagnostic Evaluation of Hyperthymic Disorders. Budapest, Animula. 1998. 

Hamilton M, White JM. Clinical syndromes in depressive states. J. Ment. Sci., 1959; 150:985-90. 

Healy D. The Antidepressant Era. Cambridge (Massachusetts, USA), Harvard University Press. 1997, p. 33. 

Heinroth JCh. Lehrbuch der Störungen des Seelenlebens. Vogel, Leipzig. 1818.

Hofmann A. The discovery of LSD and subsequent investigations on naturlally occurring hallucinogens. In: Ayd FA, Blackwell B, editors. Discoveries in Biological Psychiatry. Philadelphia, J.P. Lippincott, 1970, pp. 91-106.

Holzman PS, Kringlen E, Mathysse S, Flanagan SD, Lipton RB, Cramer G, Levin S, Lange K, Levy DL. A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch. Gen. Psychiatry, 1988; 45:641-7. 

Hyman SE. Introduction to the complex genetics of mental disorders. Biol. Psychiatry, 1999; 45:518-21.   

Jaspers K. Eifersuchtswahn : Entwicklung  einer Persoenlichkeit oder Prozess. . Z.Ges. Neurol. Psychiatr. 1910; 1:567-637. 

Jaspers K. Allgemeine Psychopathologie. Berlin/Heidelberg, Springer. 1913. 

Kahlbaum K. Die Gruppierung der psychischen Krankheiten und die Enteilumg der Seelenstoerungen. Danzig, A.W. Kaufman. 1863. 

Kety S, Elkes J, editors. Regional Neurochemistry. Proceedings of the Fourth International Symposium on Neurochemistry. Oxford, Pergamon Press. 1961. 

Kielholz P. Diagnostic aspects in the treatment of depression. In: Kielholz P, editor. Depressive Illness. Bern, Hans Hubert. 1972.

Kiloh LG, Garside RE. The independence of neurotic depression and endogenous depression. Br. J. Psychiatry, 1963; 109:451-63. 

Klein DF. Drug therapy as a means of syndromal  identification of nosologic revision. In: Cole JO, Friedman AM, Friedhoff AJ, editors. Psychopathology and Psychopharmacology. Baltimore, Johns Hopkins University Press. 1973. 

Klein DF. Endogenomorphic depression. Arch. Gen Psychiatry, 1974; 31:447-54.  

Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 5 Aufl. Leipzig, Barth. 1896. 

Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6 Aufl. Leipzig, Barth. 1899. 

Kraepelin E. Manic-depressive Insanity and paranoia. (translated by R. Mary Barclay), Edinburgh, Livingstone. 1921. 

Kuhn R, Über die Behandlung depressives Zustände mit einem iminodibenzylderivat. Schweiz. Med. Wochenschr. 1957; 87:1135-40.  

Leonhard K. Aufteilung der endogenen Psychose. Berlin, Akademie-Verlag, 1957, pp. 155-96.

Lewis A. Melancholia. A clinical survey of depressive states. J. Ment. Sci. 1934; 80:277-378.

Macht DL. Contributions to psychopharmacology. Bull. Hopkins Hosp. 1920; 31:167-73.

Mehilane L. Thomas A. Ban CODE DD Depressiivsete haäirete diagnostika koondsüsteem. Tartu, Tõlge eesti keeled, 1992, pp. 1-170.

Mendels J, Cochrane C. The nosology of depression: The endogenous-reactive concept. Am J. Psychiatry, 1968; 124 (suppl.)1:11.

Morey L. Reliability considerations  in the development of CODE-DD. In: Aguglia E, Ban TA, editors. Functional Psychoses Today. Rome, Jon Libbey, 1991, pp. 297-304.

Nardi AE,  Versiani M. Thomas A. Ban CODE-DD Avalicão Diagnostica Composta Dos Distúrbios Depressivos. Rio de Janiero, Instituto de Psiquiatria-Universidad Federal, 1990, pp. 1-300.

Neele E. Die phasischen Psychosen nach ihrem Erscheinungs-und Erbbild. Leipzig. 1949.

Overall JE, Hollister LE, Johnson M, Pennigton V. Nosology and depression and differential response to drugs. JAMA, 1966; 195:946-8.

Paykel ES. Classification of depressive patients: A cluster analysis derived grouping. Br. J. Psychiatry, 1971; 118:275-88.

Pilowsky I, Levine S, Boulton DM. The classification of depression by numerical taxonomy. Br. J. Psychiatry, 1969; 115:937-45.

Pletscher A. The dawn of the neurotransmitter era in neuropsychopharmacology. In: Ban TA, Ucha Udabe R, editors. The Neurotransmitter Era in Neuropsychopharmacology. Buenos Aires, Polemos, 2006, pp. 27-37.

Pletscher A, Shore PA, Brodie BB. Serotonin release as a possible mechanism of reserpine action. Science, 1955; 122:374-5.

Pletscher A, Shore BB, Brodie BB. Serotonin as a modulator of reserpine action in brain. J. Pharmacol. Exp. Ther., 1956; 116:84-9.

Pollitt JD. Suggestions for a physiological classification of depression. Br. J. Psychiatry, 1965; 111:489-95.

Pużyński S, Jarema M, Wdowiak J. Thomas A. Ban CODE-DD Zlożona ocean diagnostyczna zaburzeń depresyjnych. Warsaw, Prasowe Zaklady Graficzne w Koszlinie, 1989, pp. 1-232.

Raskin A, Crook T. The endogenous-neurotic distribution and a predictor of response to antidepressant drugs. Psychol. Med. 1976; 6:59-70.

Robins E, Guze SB. Classification of affective disorders. The primary-secondary, endogenous-reactive, and the neurotic-psychotic concept. In: Williams TA, Katz MM,  Shield JA, editors. Recent Advances in Psychobiology of the depressive Illnesses. Washington DC, US Government Printing Office, 1972, pp. 283-93.

Roth M, Barnes TRE. The classification of affective disorders. : a synthesis of old and new concepts. Compr. Psychiatry, 1981; 22:54-77.

Sauvages de la Croix BF. Nosologia Methodica Sistems Morborum Classes, Genera et Species, Juxta Sydenhami Mentem et Botanicorum Ordinem. Amsterdam, Frat de Tournes. 1769.

Schildkraut JJ. The catecholamine hypothesis: before and after. In: Ban TA, Healy D, Shorter E, editors. Reflections on Twentieth-Century Psychopharmacology. Budapest, Animula, 2006, pp. 254-61.

Schneider K. Die Schichtung des emotionalen Lebens und der Aufbau der Depressionszustände. Z. Ges. Neurol. Psychiatr. 1920; 59:281-5.

Schneider K. Klinische Psychopathologie. 3 Aufl. Stuttgart, Thieme. 1950.

Schneider K. Clinical Psychopathology. (translated by Mary W. Hamilton). New York, Grune & Stratton. 1959.

Shore PA, Silver SL, Brodie BB. Interaction of serotonin and lysergic acid diethylamide in the central nervous system. Experientia, 1955a; 11:272-3.

Shore PA, Silver SL, Brodie BB. Interaction of reserpine, serotonin and lysergic acid diethylamide in brain. Science, 1955b; 122:284-5.

Shorter E. A Historical Dictionary of psychiatry. New York, Oxford University Press, 2005, p. 237.

Simon P. Behavioral pharmacology. In: Ban TA, Healy D, Shorter E, editors. The Rise of Psychopharmacology and the Story of CINP. Budapest, Animula, 1998 pp. 131-4.

Snyder S, Creese I, Burt DR. The brain’s dopamine receptor labeling with [3H] dopamine and [3H] haloperidol. Psychopharmacol. Commun, 1975; 1:663-73.

Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria  (RDC) for a Selected Group of Functional Disorders 3rd edition. New Your, New York State Psychiatric Institute. 1978.

Taylor A. The Neuropsychiatric  Mental Status Examination. New York, Pergamon Press. 1986.

Teichmann G. The influence of Karl Kleist on the nosology of Karl Leonhard. Psychopathology, 1990; 23:267-76.

Wernicke C. Über die Klassifikation der Psychosen. Breslau, Slettersch Bucchandlung. 1899.

Westphal C. Über Zwangsvorstellungen. Arch. Psychiatr. Nervenkrank. 1878; 8:734-50.

Wing JK, Cooper JE, Sartorius N. Measurement and Classification of Psychiatric Symptoms. Cambridge, Cambridge University Press. 1974.

Winokur G.  The division of depressive illness into depressive spectrum disease and pure depressive disease. Int. Pharmacopsychiat., 1974; 9:5-13.

Winokur G. Unipolar depression. Is it divisible into autonomous subtypes? Arch. Gen. Psychiatry, 1979; 36:47-52

World Health Organization. ICD-10, 1987 Draft of Chapter V, Categories F00-F99, Mental, Behavioral and Developmental Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization. 1988.

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Geneva, World Health Organization. 1992.


July 2, 2020